Immunostimulants Market is expected to reach US$ 197.6 Bn by the end of 2032 | CAGR 6.2%

According to Future Market Insights' most recent industry report, the global immunostimulants market was valued at over US$ 102.2 Bn in 2021 and is expected to grow at a CAGR of close to 6.2% during the projected period (2022-2032). Against this context, the market is expected to be worth US$108.2 billion in 2022.

Immunostimulants are drugs that stimulate the immune system by accelerating the activity of immune cells, tissues, and organs and also help the body to fight against sepsis and diseases.

Get Full Access@ https://www.futuremarketinsights.com/reports/immunostimulants-market

Growing prevalence of autoimmune diseases is fueling the development of immunostimulants. Around 4% of the world's population is affected by different autoimmune diseases, which also include multiple sclerosis and rheumatoid arthritis. In the U.S., autoimmune diseases represent the third most common chronic disorder.

Further, demand for immunostimulants in countries such as India and China is expected to increase at a considerable pace. Developing economies are refining their healthcare framework, owing to increasing accessibility to resources, and increasing efforts by manufacturers to gain drug approvals for international retail.

Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15145

For instance, in November 2021, PharmaEssentia Corporation, a company based in Taiwan, announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi, long-acting interferon for the treatment of adults with polycythemia vera.

"Rising awareness regarding immunostimulants therapy for chronic diseases across emerging economies, along with increasing investments in the pharmaceutical and healthcare sectors will fuel the growth in the market over the forecast period," says an FMI analyst.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15145

Key Takeaways:

Based on product type, demand for vaccines is expected to increase at a 6.4% CAGR over the forecast period.
In terms of application, the oncology segment will account for 34.7% of the total market share by 2032.
By end user, hospital pharmacies held 34.3% of the total market share in 2021 and the trend is expected to continue over the forecast period.
The U.S. accounted for 92.85 of the North America immunostimulants market in 2021.
Sales in the Germany immunostimulants market are forecast to increase at a 6.4% CAGR over the assessment period.
Demand for immunostimulants in Japan will grow at a 6% CAGR over the forecast period.

Competition Landscape

Leading players operating in the global immunostimulants market are investing in acquisitions and collaborations to expand their global presence. They are also investing in research and development to improve their product portfolios. Key Players - F. Hoffmann-La Roche Ltd, Merck KGaA, Bayer AG, Biogen Idec, GenSci, Sinovac, BioLegend, Invitrogen, OriGene, Biorbyt, Qilu Pharmaceutical, Shijiazhuang Pharmaceutical, Amgen Inc, Johnson & Johnson, Kyowa Hakko Kirin, Bristol-Myers Squibb, Zydus Cadila, Novartis AG, Pfizer Inc, Amega Biotech, 3Sbio, Biosidus, Nanogen

Speak to our Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15145

For instance:

In August 2021, Bayer AG acquired Vividion Therapeutics to strengthen its drug discovery platform to meet the high unmet medical needs for immune-related diseases and for oncology.
In August 2020, Bristol Myers Squibb collaborated with Dragonfly Therapeutics and announced an exclusive global license for Dragonfly's IL-12 investigational immunotherapy program.

Buy Now@ https://www.futuremarketinsights.com/checkout/15145

Key Market Segments Covered in Immunostimulants Industry Research

By Product:

Colony Stimulating Factors
Interferons
Interleukins
Vaccines

By Application:

Oncology
Respiratory
Chronic & Autoimmune Disorders
Others

By End-User:

Hospital Pharmacies
Retail Pharmacies
Specialty Clinics
Online Pharmacies

Key Companies Profiled:

F. Hoffmann-La Roche Ltd
Merck KGaA
Bayer AG
Biogen Idec
GenSci
Sinovac
BioLegend
Invitrogen
OriGene
Biorbyt
Qilu Pharmaceutical
Shijiazhuang Pharmaceutical
Amgen Inc
Johnson & Johnson
Kyowa Hakko Kirin
Bristol-Myers Squibb
Zydus Cadila
Novartis AG
Pfizer Inc
Amega Biotech
3Sbio
Biosidus
Nanogen

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

This release was published on openPR.